Biogen Inc BIIB reported better-than-expected third-quarter earnings.
Biogen posted quarterly sales of $2.53 billion, beating the consensus of $2.39 billion, up 1% Y/Y and 3% at constant currency (CC). Adjusted EPS of $4.36, down 9%, beating the consensus of $3.97.
Biogen revised its FY23 revenues to decline in a low-single-digit percentage versus FY22 compared to earlier guidance of a mid-single-digit percentage decline.
Biogen shares fell 3.2% to trade at $224.30 on Thursday.
These analysts made changes to their price targets on Biogen following earnings announcement.
- Wells Fargo increased the price target on Biogen from $343 to $365. Wells Fargo analyst Mohit Bansal maintained an Overweight rating.
- RBC Capital raised the price target on Biogen from $351 to $363. RBC Capital analyst Brian Abrahams maintained an Outperform rating.
- Wedbush, meanwhile, cut the price target on Biogen from $266 to $239. Wedbush analyst Laura Chico maintained a Neutral rating.
Also Check This Out: Jim Cramer Cautions Against Investing In World's Top Scotch Whisky Distiller: 'Getting Bad Vibes'
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.